Seqens launches HPAPI manufacturing at 100-year-old site

By Jenni Spinner contact

- Last updated on GMT

(Image: Seqens)
(Image: Seqens)

Related tags: HPAPI, API, Manufacturing, France, European union

The global pharmaceutical ingredient producer has opened a high-potency active pharmaceutical ingredient unit at its century-old facility in France.

Seqens, a pharmaceutical ingredients manufacturer with locations around the globe, has launched a specialty production unit at its Villeneuve-La-Garenne, France site. The $35m (€30m) facility (opened at a ceremony attended by French president Emmanuel Macron) will tackle development and production of high-potency active pharmaceutical ingredients (HPAPIs).

The project involves an investment of $35m (€30ms) pharmaceutical synthesis. Called UPP30, the project constitutes a partnership with Belgian biotech company Mithra, reportedly for the production of a fifth-generation contraceptive molecule.

JeanPhilippe Aubert, UPP30 project director, said the company comes after years of research and labor.

"I am proud and happy to inaugurate the fruit of many years of work and to see that the SEQENS group continues to invest massively in the latest cutting-edge technologies to maintain and develop more than a hundred years of know-how and skills and thus continue to maintain in France real competences in pharmaceutical synthesis​,” he said.

Seqens’s work comprises research, development and commercialization of intermediates, APIs and HPAPIs. The company reportedly is focused on revitalizing its industrial footprint in three key areas:

  • Development of skills: the company reportedly is looking at doubling the number of work-study students and setting up a training program to build interest in pharmaceutical careers.
  • Innovation and R&D: the company employs 10% of its workforce in developing new products and innovating processes
  • Production quality and performance: Seqens reportedly prioritizes employee skills and continuous improvement at its 24 production sites.

Seqens CEO Pierre Luzeau said the company’s focus on skills and innovation will help it succeed into the future.

"Our sustainability will depend on the ability of our companies to innovate and boost productive investment in our territories. SEQENS is ready to take up the challenge by relying on innovation, R&D and the skills of our teams on our production sites​,” said Luzeau.

Related news

Related products

show more

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Register for free

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us


View more